Exercise of Warrant Shares and Call Option Shares

RNS Number : 5987B

Integumen PLC

10 June 2019

 

AIM share code: SKIN

10 June 2019

Integumen PLC

("Integumen" or "Company")

Exercise of Warrant Shares and Call Option Shares

Integumen announces that it has received notification of the exercise of call options over 1,111,111 shares in the issued share capital of Integumen ("the Call Option Shares"). The exercise of the Call Option Shares amounts, in aggregate, to a cash value of £177.  The Company also announces that it has received notification of the exercise of warrants over 5,000,000 shares in the issued share capital of Integumen ("the Warrant Shares"). The exercise of the Warrant Shares amounts, in aggregate, to a cash value of £75,000.

The Call Option Shares and the Warrant Shares are expected to be admitted to trading on AIM on or about 14 June 2019 and will rank pari passu with the ordinary shares of the Company in issue.

Total voting rights

The Company's total issued capital, after the issue of the Call Option Shares, will be 960,284,795 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

Contacts

Integumen plc	Gerard Brandon, CEO	[phone]
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	[phone]
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker	[phone]

About Integumen:

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

 

END

 

 

MSCCKCDQOBKDQAK